UBS lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $546 from $553 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Strong Revenue Performance and Promising Prospects Justify Buy Rating
- FDA awards second batch of National Priority Vouchers
- Vertex Pharmaceuticals Q3 2025 Earnings Call Highlights
- Vertex Pharmaceuticals: Promising IgAN Market Position with Povetacicept’s Superior Efficacy and Patient-Friendly Administration
- Vertex Pharmaceuticals price target lowered to $415 from $423 at RBC Capital